EditForce, Inc. announced that our "Development of an Innovative Treatment for Myotonic Dystrophy Type 1 by a Sequence--Specific RNA Binding Protein Targeting Pathogenic CUG Repeat
March 22, 2023
In the Program AMED supports the development of practical applications for drugs undertaken by drug discovery startups, subject to investment from venture capital firms registered by AMED specializing in drug development and providing hands-on business management and commercialization support. ("Certified VCs").
We applied for the Program with support and investment from Newton Biocapital as Certified VCs, and are now entitled to receive a subsidy from AMED for development of EF-210 since the investment from Newton Biocapital has been made by March 22, 2023, as stated in the "FUND RAISING THOROUGH THIRD-PARTY ALLOTMENT OF SHARES.”
Through the Program, we will promote the non-clinical and clinical development of EF-210, and strive to realize a drug for Myotonic Dystrophy Type 1 as soon as possible.